| Outcome definition | Cohort | Subjects | Number of events | Total follow-up, years | Adjusted# HR (95% CI) |
|---|---|---|---|---|---|
| Composite outcome of cervical dysplasia and cancer | Full SLE | 4550 | 121 | 23136 | 2.12 (1.65–2.71) |
| Antimalarials* | 1783 | 26 | 6564 | 1.52 (1.00–2.33) | |
| Immune-suppressives* | 1981 | 73 | 9002 | 2.72 (2.01–3.67) | |
| General population | 28113 | 336 | 155543 | REF | |
*Subsets of “Full SLE”. Data on exposure from the Prescribed Drug Register 2006–. #Adjusted for level of education, healthcare utilization, number of children, marital status, family history of cervical cancer, prior cervical screening during the last 5 years before start of follow-up, and start year.